New hope for leukemia patients: experimental drug aims to boost chemotherapy results
NCT ID NCT07223814
Summary
This study is testing whether adding an experimental drug called bleximenib to standard chemotherapy improves outcomes for adults newly diagnosed with a specific type of acute myeloid leukemia (AML). The trial will include 875 participants who will receive either bleximenib or a placebo (inactive pill) along with their chemotherapy, and neither patients nor doctors will know which treatment is given. The main goal is to see if the combination helps patients live longer without their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
DE-Ulm-UNIKLINKULM
RECRUITINGUlm, Germany
Contact
-
NL-Breda-AMPHIA
RECRUITINGBreda, Netherlands
Contact
-
NL-Den Haag-HAGA
RECRUITINGThe Hague, Netherlands
Contact
-
NL-Eindhoven-MAXIMAMC
RECRUITINGEindhoven, Netherlands
Contact
-
NL-Leeuwarden-FRISIUSMC
RECRUITINGLeeuwarden, Netherlands
Contact
-
NL-Nieuwegein-ANTONIUS
RECRUITINGNieuwegein, Netherlands
Contact
-
NL-Rotterdam-ERASMUCMC
RECRUITINGRotterdam, Netherlands
Contact
-
US-Cincinnati OH-CINCY
RECRUITINGCincinnati, Ohio, 45219, United States
Contact
Conditions
Explore the condition pages connected to this study.